



Strategies to Enhance Bioavailability of Drugs In Nasal Drug Delivery Systems

Shahid Showkat, Loveleen Preet Kaur, Navneet Kaur, Mohit Kumar*
Department of Pharmaceutics, RIMT University, Mandi Gobindgarh, Punjab

ABSTRACT

Nasal drug delivery holds promise for improved bioavailability, offering rapid onset of action and bypassing first-pass metabolism. This article explores advanced strategies to optimize drug absorption via the nasal route. It discusses the utilization of technology for precise drug targeting and enhanced permeation across mucosal barriers. Additionally, it examines the role of polymers in prolonging residence time and promoting sustained drug release. Permeation enhancers and microemulsions are explored for their potential to overcome biological obstacles and enhance drug absorption. Moreover, advancements in nasal delivery device design are highlighted for their pivotal role in ensuring accurate dosing and patient compliance. By synthesizing these strategies, the article aims to guide researchers and pharmaceutical developers towards the creation of more effective nasal drug delivery systems with enhanced bioavailability and therapeutic outcomes.

Keywords: Nasal vaccines, Bio adhesive polymers

*Corresponding Author Email: mohitmehta9@gmail.com
Received 10 February 2024, Accepted 03 March 2024

Please cite this article as: Kumar M *et al.*, Strategies to Enhance Bioavailability of Drugs In Nasal Drug Delivery Systems. American Journal of Pharmacy & Health Research 2024.

INTRODUCTION

Drug conveyance using the nose has a long history. It was first recorded as a hard copy in the Indian type of medication, called Ayurveda. "Nasya Karma" is a nasal medication conveyance framework for 31 distinct areas and fundamental infections¹ The dynamic fixings utilized are oils, powder, steam, and smoke², These days, intranasal drug application is generally regularly utilized for the treatment of areas of inflammation, hypersensitive rhinitis, normal rhinitis, or for facilitating nasal clogs. Frequently utilized dynamic fixings are, for instance, glucocorticoids, decongestants, or allergy meds, which can be tracked down in nasal splashes and drops from one side of the planet to the other³. An extraordinary benefit of nasal medication organization is fast medication retention because of the predominant states of being of the nose, similar to great blood flow of the nasal mucosa, bringing about a speedy area's impact. As a result of the quick areas ingestion, an inadvertent fundamental circulation of the medication is forestalled, and the related symptoms of the dynamic fixing are stayed away from⁴. Lately fundamental nasal medication organization has acquired significance as a promising treatment choice for oral and parenteral medication application⁵. The fundamental benefit of nasal organization is the counteraction of first-pass digestion, the high penetrability of certain medications in the nasal epithelium, the quick retention of the medication through this film, the fast beginning of activity, the better consistency and solace for the patient, and the maintained and delayed impact contrasted with other conveyance frameworks like oral medication conveyance frameworks⁶. Corrosive touchy medications, for example, peptide chemicals or proteins, which would be harmed in the GIT, likewise tranquilize with a polar dynamic substance gathering can be applied nasally, and drugs that just are not consumed orally. A consideration of pervasion enhancers empowers the assimilation of significant medication structures and, for the most part, expands the nasal medication take-up⁷. Quick medication retention and hence quick areas and fast fundamental impact, as well as the accomplishment of high foundational blood levels, are empowered by serious areas of strength for the stock prevailing in the nasal mucosa. Nasal medication organization is not difficult to do yourself or by nursing staff, has a generally safe rate of injury or contamination for blood-borne infections like hepatitis B or HIV, and is harmless and effortless⁸.

The nose - anatomy and function:

The nose is one of the essential tactile organs. Its external part consists of a hard part and a cartilaginous part. The strong, hard aspect of the nose, the nasal pyramid, contains on the two sides facing up the nasal augmentation of the front-facing bone, on the sides facing the expansion

of the upper jaw, and in the center the nasal bone. The portable cartilaginous piece of the nose remembers the three-sided ligament and the tip ligament for each side. Along with the nasal bones, the supporting ligament tissue decides the external state of the nose and safeguards the nasal skeleton⁹. The inside of the nasal cavity (NC) reaches out from the nostrils to the back nasopharynx and is parted into two comparative parts by the nasal septum⁴. The total volume of the NC is around 15 mL and has a general surface of 150 cm². A layer of bodily fluid cells and hairs, cilia, cover the whole internal surface of the nose¹⁰.

The area of the vestibular district is at the launch of the nasal entry. It is made out of diverse squamous epithelial cells and keratinized epithelial cells with nasal hairs, additionally called vibrissae.¹¹ The chamber isolates the nasal vestibule from the respiratory plot. In the foremost district, the chamber as a momentary epithelial locale is made out of stratified squamous epithelial cells, and the back locale comprises of pseudo stratified columnar cells introducing microvilli¹². The biggest area, the respiratory locale, is found subsequently. It is otherwise called the conchae and can be additionally partitioned into three nasal conches, which are situated on the horizontal walls of the nasal cavity upper, center, and lower nasal turbinate. These nasal turbinates make expanded contact between the mucous layer and the breathed-in air by creating tempestuous airflow through the nasal sections. The nasal mucosa is known to be a critical piece of the fundamental medication organization. It is made out of the epithelium, the basal layer, and the lamina propria. The cells of the respiratory epithelium are covered by around 300 microvilli per cell and are exceptionally vascularized¹³. The region stretching out from the highest point of the NC down to the septum and side wall is known as the olfactory district. This locale likewise contains chiefly four cell types: supporting cells, basal cells, microvillar cells, olfactory receptor neurons, and to a small degree trigeminal neurons. Underneath these epithelial cells lies the lamina propria, which contains veins, lymphatic framework, connective tissue, axons, Bowmann's Organ, and perivascular spaces¹⁴. The nasal mucosa is somewhere in the range of 2 and 4 mm thick. A 5-um wide bodily fluid layer in the nasal section covers the epithelial cells. Its motivation is to trap and move unfamiliar particles. The bodily fluid discharge has a pH in the scope of 5-6.5 and is comprised chiefly of water, as displayed in **Table 1**¹⁵

Table 1. Composition of nasal mucosa

Composition	Proportion (%)
Albumin, immunoglobulin's, lactoferrin, lysozyme and other proteins	1
Glycoproteins	2
Inorganic salts	1
Lipids	<1
Water	95

Besides, the bodily fluid has a water-holding limit and empowers proficient intensity movements. Likewise, the top region of the bodily fluid shows electrical movement¹⁶.The immunoglobulin's situated inside the bodily fluid layer are IgA, IgE, and iGg¹⁵. Further area security against microorganisms entering the body through the mucosal layer is given by the mucosal-resistant framework situated in the nasopharynx. In the mucosal tissue of the nose, resistant exercises are furthermore connected to lymphoid tissue the nasopharynx-related lymphoid tissue. It is made out of lymphoid tissue, immune system microorganisms, B-cells, and antigen-introducing cells and is covered by an epithelial layer. Furthermore, in this epithelial layer, there are memory cells, which are explicit for the transportation of antigens across the epithelium¹⁷

NASAL DRUG DELIVERY SYSTEMS:

The physiochemical properties of the medication play a significant part in nasal medication retention. If the medication has a huge size (more prominent than 1 Kilo dalton (kDa)), is excessively lipophilic (can't break up in the nasal mucous film), or has a serious level of ionization (adversely charged particles are repulsed by the adversely charged nasal mucosa), it can't enter the mucosa and a huge extent is pre-foundationally corrupted and wiped out. Nasal medication conveyance can be influenced by a few unique factors: the pH of a medication influences its strength and the level of ionization and can bother the nasal mucosa¹⁸.

Local used drugs for nasal drug delivery

As depicted toward the start, the nearby utilization of medications using the nose is deeply grounded. Nasal showers and drops for nearby treatment of an inflamed or obstructed nose are accessible practically around the world. Especially hydrophobic medications or medications with low sub-atomic weight are appropriate for nearby nasal applications. For instance, naphazoline is utilized to decrease the enlarging of nasal colds, budesonide is an enemy of inflammatory corticosteroids for sensitivities, and levocabastine is an H1-receptor bad guy and allergy med. An outline is given in Table 2.

Table 2: Local used drugs for nasal drug delivery on market

Class of drugs	Active ingredient	Products
Antihistamines	Azelastine	Allergodil®
	Cromoglicic acid	Pollicrom®
	levocabastine	Levocamed®
Glucocorticoids	Beclomethasone dipropionate	Rhinivict®
	Fluticasone furoate	Avamys®
	Mometasone furoate	Momeallerg
	Budesonide	Budapp®

Sympathomimetic	Naphazoline	Rhinex®
	Oxymetazoline hydrochloride	Nasivin®
	Xylometazoline hydrochloride	Olynth®

Administering drugs directly at the site of action requires a lower drug dosage than systemic administration, and the symptoms of the disease are rapidly alleviated³.

Systemic drug delivery:

There are different vehicle courses accessible for fundamental medication conveyance: using the transcellular course, mostly slight lipophilic mixtures pass across the nasal epithelium and through the blood or lymphatic framework into the foundational dissemination. On this transport course, the medication needs to go through the blood-brain barrier (BBB) to get to the human mind, is presented to the hepatic first-pass instrument, and has an expanded foundational load. From the respiratory locale, medications can be communicated straightforwardly into the human cerebrum stem and further regions of the mind by converging with the fringe trigeminal neurons through endocytosis along the parts of the trigeminal nerves. A lot bigger extent of the medication is shipped to the mind through the olfactory district. As shown in Figure 1¹⁹




Figure 1: Different pathways for drug transport to the brain after nasal drug administration.

The drug can be transported to the human brain via two methods, the neuronal transport route and the extracellular transport route. During the neuronal transport route, the drug can internalize

with the olfactory sensory neurons through endocytosis or pinocytosis. The drug is then released in the olfactory bulb through exocytosis and further travels to the human brain. This transport route can take hours or days. On the other hand, the extracellular transport route takes only a few minutes and is the fastest method of transport ¹⁹

Drug delivery from the nose to the brain:

The BBB is found midway in the neurovascular unit and comprises a firmly shut monolayer organization of veins compromised by energized endothelial cells shaping the mind and spinal string vessels. This layer forestalls the free trade of substances between the blood flow and the cerebrum. The epithelial cells of the cerebrum are firmly associated with close intersections and disciple intersections. Tight intersections control the section of substances between the mind and the blood, or the other way around²⁰.The BBB directs the expulsion of metabolites and the assimilation of required supplements into the focal sensory system and keeps up with the synthetic structure of the neuronal milieu to guarantee healthy neuronal capability. Moreover, the BBB safeguards the mind against the entrance of platelets, microbes, transmitters, and neurotoxic plasma components ²¹. One chance to evade the BBB is infusions regulated intrathecally, intracerebro ventricularly, or intraparenchymally. Thus, the medication directly affects the focal sensory system's cerebrospinal fluid. In any case, these are obtrusive techniques that must be done via prepared experts, and these strategies have an extra gamble of contamination ²². A painless method for dodging the BBB and the blood-cerebrospinal fluid boundary is to direct medications through the nose to the mind (N2B). The nose isn't just situated in the quick area of the mind, however, it likewise contains unique nerves, the olfactory and the trigeminal nerve, which have an immediate association with the cerebrum, free to the furthest reaches of the BBB²². To dodge the BBB, examine the over-the-counter schizophrenic medication quetiapine fumarate in the mix with liposomal drug conveyance frameworks. Schizophrenia is a disorder of the focal sensory system, and in this way, the medication needs to enter the mind to be viable. Quetiapine fumarate has an oral bioavailability of 7-8% because of its low water dissolvability. It is profoundly delicate to the primary pass instrument and is killed upon contact with the BBB. By interfacing it with a liposome made out of cholesterol and egg phosphatidylcholine, the medication accessibility can be expanded to 32.61%²³, Concentrates on showed the way that not just little dynamic substances can be absorbed through the nose, but additionally ingestion of proteins, peptides, stem cells, infections, as well as expected nucleotides from the N2B²², The fundamental fibroblast development factor is a 16.5 kDa protein that is utilized in stroke and has neuroprotective properties. Due to its size, it can't conquer the BBB

and should be controlled straightforwardly intracerebroventricularly or intraparenchymally. Zhao et al. researched this protein in the mix with a nanoliposomal drug conveyance framework in rodents. The trial creatures were noticed and examined for 21 days. The rodents treated with the medication nano liposome edifices showed an improvement in the harmed cerebrum tissue and the survival rate was 57%²⁴.

Nasal vaccines:

Immunization is the organization of live-weakened antibody microorganisms, non-illness-causing microorganisms, or segments of microorganisms fully intent on inoculating the organic entity against an irresistible infection. Most customary immunizations are directed parenterally because they are frequently hard to retain through the mucous films and have little solidness in the GIT in the event of oral inoculations. Parenteral inoculation offers fast blood improvement and great bioavailability, yet additionally a few inconveniences like an expanded gamble of disease, low tolerant consistency, and the requirement for the organization via prepared staff²⁵, Nasal antibodies are connected to nasal conveyance frameworks for expanded steadiness and bioavailability. Nasal conveyance frameworks shouldn't surpass 100 nm in that frame of mind; up to this size, they can enter the nasal mucosa boundaries and have roughly a similar size proportion as an infection. The ideal size range is somewhere in the range of 20 and 80 nm width²⁶. To be successful, nasal immunization requires a connection with the resistant framework. The nasal framework for actuation of the safe framework is the nasopharynx-related lymphoid tissue, which in the human nose is made out of the Waldeyer's ring. The excitement of the nasopharynx-related lymphoid tissue with the stock of antigens causes areas of strength for a cell-resistant reaction in the body, which happens on a mucosal as well as on a foundational level²⁷. Cationic liposomes are protected, powerful nasal medication conveyance frameworks²⁸, examined cationic liposomes in a blend with ovalbumin. The examinations showed that intranasal organization of ovalbumin-stacked cationic liposomes improved antigen take-up by dendritic cells in nasal-related lymphoid tissue. A safe reaction is incited through antigen-specific responses²⁸ Nasal antibodies are harmless, effortless to utilize, and can be created at cost. Up to this point, a couple of items are accessible and available, as preclinical investigations are generally performed on rodents. The distinctions between a rat and a human nose render execution, application well-being, and forecast of efficiency²⁶.

Various factors that affect bioavailability of nasally administered drugs as follows:

I. Organic elements²⁹

- Primary elements

- Biochemical changes

II. Physiological elements

- Blood supply and neuronal guideline
- Nasal emissions
- Mucociliary clearance(MCC)
- Obsessive circumstances
- Ecological circumstances
- Film penetrability

III Physicochemical properties of medication ²⁹

- Sub-atomic weight and size
- Solubility
- pKa and segment coefficient
- Polymorphism
- Synthetic condition of medication
- Physical condition of medication

VI Physicochemical properties of the plan

- PH
- Osmolarity

I. Organic elements

- Primary elements: There are five unique segments of the nasal pit: nasal vestibule, chamber, respiratory region, olfactory district, and the nasopharynx. These designs and the sort of cells, thickness, and number of cells present in that locale impact the porousness. Retention enhancers utilized in blends with drugs increment the pervasion of mixtures ³⁰.
- Biochemical changes: Enzymatic hindrance to the conveyance of medications is nasal mucosa due to the presence of countless proteins, which incorporate oxidative and conjugative catalysts, peptidases, and proteases. These chemicals are liable for the debasement of medications in the nasal mucosa and result in the production of a pseudo-first-pass impact. Digestion of nasal decongestants, alcohols, nicotine, and cocaine is expected to affect the P450 subordinate monooxygenase framework ³¹.

II. Physiological elements

- Blood supply and neuronal guideline: The nasal mucosa is a profoundly penetrable site. A high blood supply because of parasympathetic feelings gives clogs, and a low blood supply because of thoughtful excitement gives unwinding. Manage the ascent and fall in the measures of medication pervaded, separately³². Given the above perceptions, we can reason that the expanded penetrability of a compound is because of parasympathetic excitement.
- Nasal emissions: are delivered by front-serous and seromucous organs. Bodily fluid creation is around 1.5–2 liters per day. The porousness of medication through the nasal mucosa is impacted by the thickness of nasal discharge, solubility of medication, pace of penetration of medication, and pH of the nasal cavity³³.
- Mucociliary clearance (MCC): At the point when a substance is nasally directed, it is cleared from the nasal depression in 21 min by MCC because mucociliary clearance is the ordinary protection component of the nasal cavity, which clears substances sticking to the nasal mucosa and is cleared in GIT by depleting in the nasopharynx. Drug saturation is improved by expanding contact time between medication and bodily fluid film because of diminished MMC; however, expanded MCC diminishes drug penetration³⁴. Obsessive circumstances: Mucociliary disfunctioning, hypo or hyper secretions, and disturbance of the nasal mucosa happen because of sickness, for example, the normal cold, rhinitis, atrophic rhinitis, and nasal polyposis, and drug penetration is impacted by this³⁴
- Ecological circumstances: A moderate decrease in the pace of MCC happens at the temperature of 240C, it has been anticipated that a direct expansion in ciliary beat recurrence happens with an expansion in temperature³⁴.
- Film penetrability: Ingestion of the medication through the nasal course is impacted by film porousness, which is the most significant component. The huge sub-atomic weight medications and water solvent medications like peptides and proteins have low film porousness and are thus assimilated through endocytic transport in smaller sums³⁴.

III. Physicochemical properties of medication:

- Sub-atomic weight and size: The drug is still up in the air due to its sub-atomic weight, sub-atomic size, hydrophilicity, and lipophilicity of the compound. For intensified 1-KDa, bioavailability can be straightforwardly anticipated from information on MW. As a rule, the bioavailability of these enormous particles goes from 0.5% to 5%. Physicochemical properties of the medication don't essentially influence penetration of medication LT 300 Da, which will for the most part pervade through fluid channels of the

film. Conversely, for builds with MW 300, the pace of penetration is exceptionally delicate³⁵.

- Solubility: The main consideration in deciding the retention of medication through organic films is drug solvency. As nasal discharges are more watery, medication ought to have fitting fluid dissolution ability for expanded disintegration. Lipophilic medications have less dissolvability in the fluid emissions. Water-dissolvable medications are consumed by aloof dissemination and lipophilic medications through dynamic vehicles relying on their solvency³⁵.
- Lipophilicity: The penetration of the compound typically increases through nasal mucosa with expansion in lipophilicity. The nasal mucosa is fundamentally lipophilic, and the lipid area assumes a significant part in the boundary capability of these films even though they have a few hydrophilic qualities. The fundamental bioavailability of many medications is diminished because of the abundance of hydrophilicity. In such cases, a prodrug approach is advantageous³⁶.
- pKa and segment coefficient: According to the pH parcel hypothesis, unionized species are consumed better compared to ionized species, and a similar reality is valid on account of nasal retention. There is a consistent connection between pKa and the nasal ingestion of these medications. With an expansion in lipophilicity or the parcel coefficient of the medications, their fixation in natural tissues increases. The assimilation pace of aminopyrine expanded with the expansion in pH and was found to fit well with the hypothetical profile. The main consideration in administering nasal retention is the plot coefficient³⁶.
- Polymorphism: Polymorphism is the significant boundary in the nasal medication item improvement, which is controlled by particulate structure. Polymorphism is known to influence the disintegration of medications, and their retention through natural films is impacted by polymorphism. This variable ought to be carefully considered in the dose structure advancement for nasal conveyance³⁷.
- Synthetic condition of medication: Retention of the substance is not entirely set in stone by the synthetic type of medication in which it is introduced to the nasal mucosa. Synthetically modifying a medication particle by adding a bio-cleavable lipophilic moiety is the option for further developing retention of the medication, which doesn't have the desired ingestion properties. The prodrug approach gives numerous extra difficulties that

should be conquered in the medication item's formative cycle. The harmfulness of the prodrug itself should be completely evaluated³⁷.

- **Physical condition of medication:** Molecule size and morphology of medication are two fundamentally significant properties for particulate nasal medication items. These two boundaries ought to be controlled to get appropriate medication disintegration properties in the nostrils. Too-fine particles under 5 microns ought to be kept away because they might get breathed into the lungs. By and large, particles in the 5–10-micron range are saved in the nostrils³⁷.

VI. Physicochemical properties:

- **pH:** The degree of medication is not entirely set in stone by pH segment speculation, thus it is connected with detailing pH³⁸.
- **Osmolarity:** Detailing constitution considerably influences the nasal mucosa; by and large, an isotonic plan is liked. Some researchers concentrated on the impacts of detailing osmolarity on the nasal retention of secretin in rodents. They observed that all cells of the nasal mucosa were impacted by the centralization of sodium chloride in the detailing, and the retention arrived at its greatest at a 0.462 M sodium chloride fixation. At this focus, shrinkage of epithelial cells was noticed. Subsequently, the Constitution is additionally affecting medication assimilation³⁸

STRATEGIES FOR IMPROVING THE BIOAVAILABILITY OF NASAL DRUG DELIVERY SYSTEMS:

Various tactics were utilized to improve the Bioavailability of the drug in the nasal mucosa, include the following:

Improve the nasal residence time:

Mucociliary clearance acts to eliminate the unfamiliar bodies and substances from nasal mucosa as fast as could be expected. One approach to deferring freedom is to apply the medication to the foremost piece of the nasal cavity, an impact that is still up in the air by the kind of dose structure utilized. The readiness could likewise be formed with polymers, for example, methylcellulose, hydroxy propyl methyl cellulose, or polyacrylic corrosive, in which consolidation of the polymer expands the thickness of the definition and goes about as a bioadhesive with bodily fluid³⁹. Another worthwhile method for expanding the nasal obstruction time is utilizing biodegradable microspheres as a transporter for drug conveyance. Biodegradable microspheres enlarge within the sight of water, in this way expanding the consistency. This peculiarity prompts an increment in nasal private time³⁹.

Table 3: Bio adhesive polymers used in nasal drug delivery

Polymer	Characteristics
Cellulose derivatives <ul style="list-style-type: none"> Soluble: Hydroxypropyl methylcellulose, Hydroxypropyl cellulose, Methyl cellulose, carboxymethyl cellulose. Insoluble: Microcrystalline cellulose and ethyl cellulose. 	<ul style="list-style-type: none"> Prolong nasal residence time Sustain the release of drug due to high viscosity Act as absorption enhancer Increase intranasal bioavailability
Polyacrylates <ul style="list-style-type: none"> Polycarbophils carbomers 	<ul style="list-style-type: none"> Having good mucoadhesive and gel forming capacity. Capable of attaching mucus surfaces and make the strong contact between the formulation and membrane surface
Starch <ul style="list-style-type: none"> Maize starch Degradable starch microspheres 	<ul style="list-style-type: none"> It improves both Hydrophobic & Hydrophilic macromolecular drugs It is used in macroparticulate nasal drug delivery system.
Chitosan	<ul style="list-style-type: none"> Its insoluble in neutral and alkaline PH It forms water soluble salts with inorganic and organic acids It has low cost and is Biodegradable and Biocompatible.

Enhancing nasal absorption:

The term assimilation enhancer normally alludes to a specialist whose capability is to increment retention by improving layer penetration rather than increasing dissolvability in this way. Such specialists are sometimes more explicitly named saturation enhancers⁴⁰. The component of activity of the assimilation enhancer is increasing the rate at which medication goes through the nasal mucosa by adjusting the construction of epithelial cells here and there (penetration enhancers). This should be achieved without causing harm or permanent change to the nasal mucosa^{39,5}, By and large, the ingestion enhancers might act through one of the accompanying instruments^{41,42}.

1. Open tight intersections
2. Decline Mucociliary clearance
3. Restrain protein action
4. Diminish bodily fluid consistency or flexibility.

Certain medication atoms might be inadequately porous across the nasal epithelium and may show a lack of bioavailability. Albeit nasal saturation enhancers can work on the bioavailability and restorative adequacy of nasal items, their poisonousness ought to be considered while creating dose structure. One of the most well-known issues revealed with pervasion enhancers is

nasal aggravation^{42,43}. The ideal entrance enhancers ought to have the accompanying qualities. It ought to convey the medication particle across the cell from the apical to the basolateral surface. The transporter ought to be powerful, pharmacologically dormant at the focus utilized (non-harmful and non-allergenic), and have no aggravation or problematic information on the phone film. The transporter ought to be viable with drugs and genuinely as opposed to covalently related to the atom. The method of activity of the transporter ought to be known, ideally including a characteristic interaction, for example, particle transport/cell flagging⁴⁴.

Adjusting drug structure:

Adjusting medication structure without modifying pharmacological movement is one of the worthwhile ways of working on nasal retention. Here, a change in physiochemical properties, for example, sub-atomic size, atomic weight, pKa, and solvency, is great for nasal medication retention^{8,45,46,47}. Planning for nasal detailing relies upon the remedial need of the specific medication atom, term of activity, and length of treatment. Both controlled discharge and customary delivery drug conveyance are possible through the nasal course. The prerequisite for the drug excipients relies upon the method of medication conveyance that is to say, nearby or fundamental medication conveyance^{48,49,50,60}. The nasal details are accessible and many examinations have been done, as thus far, a portion of these conveyance frameworks and their key elements are summed up beneath.

Types of Absorption Enhancers:

Various types of penetration enhancers can be used as following:

Surfactants: Surfactants are the best pervasion enhancers, yet epithelial harmfulness, ciliostatic action, and nasal bothering are the principal disadvantages. Similar pharmacokinetics of intranasal conveyance of salmon calcitonin were considered with different surfactants. A 10-fold expansion in serum calcitonin levels over the benchmark group (calcitonin without surfactant) was seen in plans consolidated with surfactants⁵¹.

Cyclodextrins (Cd): Methylated subsidiaries of Album, particularly β -Compact disc and α -Cd are fantastic solubilizers and assimilation enhancers. Be that as it may, concentrates on irregular methyl- β - Cd (20% or more) uncovered serious harm to the nasal mucosa's trustworthiness. Ongoing examinations of lipophilic medications in the nasal medication conveyance framework with Compact disc included estradiol (decline in portion), morphine HCl, midazolam (upgraded nasal assimilation), and dihydroergotamine (further developed steadiness)^{52,53}.

Unsaturated fat salts: These mixtures increment the ease of phospholipid spaces and question layers to improve the retention, for instance, oleic corrosive, methyl oleate, lauric corrosive, caprylic corrosive, and phosphatidylcholine⁵⁴.

Phospholipids: Phospholipids are amphiphilic particles comprised of hydrophobic tails and a hydrophilic head. Phosphatidylcholines are surface-dynamic amphiphilic intensifies created in natural films and liposomes. A few reports have shown up in the literature demonstrating the way that these phospholipids can be utilized as enhancers for fundamental nasal medication conveyance. considered intranasal organization of insulin with dodecanoyl-L-phosphatidylcholine in sound human workers. They found that intranasal insulin was caught up in a portion subordinate way with slight or no nasal bothering⁵⁵.

Bile Salts: These mixtures were viewed as less bothering to the nasal mucosa, have lower haemolytic movement, and less protein discharge than different surfactants. Likewise, it has been accounted for that bile salts might influence the nasal film by making transient pores and upgrading its porousness, or structure to invert micelles inside nasal layers, which insulin monomers can diffuse through polar channels from the nares into the circulatory system. It has been shown that bile salts cause nasal bothering when utilized over a focus of 0.3%. Sodium glycodeoxycholate (NaGDC) is more viable as a retention advertiser in the nasal mucosa than sodium glycocholate (NaGC)⁵⁶.

Chelating Specialists: Materials used as chelating specialists are ethylenediaminetetraacetic corrosive (EDTA), citrus extract, sodium citrate, and sodium salicylate. The instrument of activity as a chelating specialist is by disrupting capsolyacrylates⁵⁴.Glycols Models for glycols going about as ingestion enhancers are n-glycerols and n-ethylene glycols⁵⁴.

Enzymatic Inhibitors: Nasal mucosa is a functioning enzymatic hindrance as it contains an assortment of processing compounds. Different sorts of enzymatic inhibitors can be utilized to keep away from debasement, like the utilization of proteases and peptidases inhibitors chiefly in the detailing of protein and peptide atoms. For instance, bestatine and comostate amylase are utilized as aminopeptidase inhibitors, and leupeptin and aprotinin as trypsin inhibitors engaged with calcitonin debasement. The enzymatic debasement of leucine encephalin and human development chemicals can be stayed away from by the utilization of bacitracin, amastatin, norleucine, and puromycin^{5,57}.The utilization of specific ingestion enhancers additionally keeps away from enzymatic corruption, for example, bile salts and fusidic acid. Disodium EDTA lessens the enzymatic debasement of beta-sheet breaker peptides utilized in the treatment of Alzheimer's illness^{5,57}.

Prodrugs: Intranasal drugs are regularly managed as arrangements or as the need might arise to go through a disintegration cycle before retention. Lipophilic medications effectively go through bio membranes; in any case, they are ineffectively water-dissolvable. Along these lines, they ought to be managed as a prodrug with the higher hydrophilic person to make conceivable the creation of a watery nasal plan with a reasonable fixation. Once in the circulation system, the prodrug should be immediately changed over completely to the parent drug⁵⁸. A few scientists have likewise utilized the prodrug approach for working on the enzymatic security of medications. For instance, (Yang *et al.*) expressed that the L-aspartate- β -ester prodrug of acyclovir was more porous and less labile to enzymatic hydrolysis than its parent drug. What's more, the expected utilization of prodrugs to safeguard peptide drugs from nasal enzymatic debasement has been examined and recommended as a strong system to build the bioavailability of peptides when directed intranasally⁵⁸.

Cosolvents: A basic way to deal with getting higher dissolvability of medication is to utilize a blended dissolvable framework or a cosolvent. Such cosolvents should be non-poisonous, chemically satisfactory, and, for nasal conveyance, a non-aggravation to the nasal mucosa. Solvents frequently utilized in nasal medication conveyance are glycerol, ethanol, propylene glycol, and polyethylene glycol^{54,59}.

Future Prospectives and Conclusion

In the forthcoming article, "Strategies to Enhance Bioavailability of Drugs in Nasal Drug Delivery Systems," we delve into innovative approaches poised to revolutionize drug delivery efficacy. Exploring nasally administered drugs' potential, we dissect cutting-edge strategies aimed at augmenting bioavailability. From novel formulations leveraging nanotechnology to advances in mucoadhesive polymers, the article navigates the intricate landscape of nasal drug delivery optimization. Additionally, it explores the role of permeation enhancers and microemulsions in overcoming biological barriers, fostering enhanced drug absorption and systemic circulation. Furthermore, the article illuminates recent breakthroughs in nasal delivery device design, fostering precise and efficient dosing while ensuring patient comfort and compliance. By synthesizing these advancements, the article aims to provide a comprehensive roadmap for researchers and pharmaceutical innovators, facilitating the development of next-generation nasal drug delivery systems with heightened bioavailability and therapeutic efficacy.

Conflict of Interest:

There is no conflict of interest to disclose.

REFERENCES:

1. Agarwal R, Rani M. Significance of Nasa & Nasya—A Critical Review. *Punarnav*, 2 (1). 2014;1
2. Sheetal B, Bamnikar M, Baheti SR. Mechanism of nasya: an overview. Shekade SV, Shirolkar SV, Chaudhari Y. A review on microemulsion drug delivery system for nasal application. *Journal of Pharmaceutical Sciences and Research*. 2020;12(1):63-73.
3. Aulton ME, Taylor K, editors. *Aulton's pharmaceuticals: the design and manufacture of medicines*. Elsevier Health Sciences; 2013.
4. Akel H, Ismail R, Csoka I. Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer's disease. *European Journal of Pharmaceutics and Biopharmaceutics*. 2020 Mar 1; 148:38-53.
5. Mundlia J, Kumar M. Nasal drug delivery-an overview. *International Journal of Pharmaceutical Sciences and Research*. 2015 Mar 1;6(3):951.
6. Thorat S. Formulation and product development of nasal spray: an overview. *Scholars journal of applied medical sciences*. 2016;4(8D):2976-85.
7. Moinuddin S, Razvi SH, Uddin MS, Fazil M, Shahidulla SM, Akmal MM. Nasal drug delivery system: A innovative approach. *Perception*. 2019;15:16.
8. Merkus P, Ebbens FA, Muller B, Fokkens WJ. The 'best method of topical nasal drug delivery: comparison of seven techniques. *Rhinology*. 2006 Jun 1;44(2):102-7.
9. Koppe T, Giotakis EI, Heppt W. Functional anatomy of the nose. *Facial Plastic Surgery*. 2011 Apr;27(02):135-45.
10. Lokhande SS. A review on intranasal drug delivery system with recent advancement. *Research Journal of Topical and Cosmetic Sciences*. 2018;9(1):12-8.
11. Jain A, Hurkat P, Jain A, Jain A, Jain A, Jain SK. Thiolated polymers: pharmaceutical tool in nasal drug delivery of proteins and peptides. *International journal of peptide research and therapeutics*. 2019 Mar 15;25(1):15-26.
12. Shekade SV, Shirolkar SV, Chaudhari Y. A review on microemulsion drug delivery system for nasal application. *Journal of Pharmaceutical Sciences and Research*. 2020;12(1):63-73.
13. Jaiswal PL, Darekar AB, Saudagar RB. A recent review on nasal microemulsion for treatment of CNS disorder. *International Journal of Current Pharmaceutical Research*. 2017;9(4):5.

14. Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. *Journal of controlled release*. 2018 Jul 10; 281:139-77.
15. Hussein NR, Omer HK, Elhissi AM, Ahmed W. Advances in nasal drug delivery systems. In *Advances in medical and surgical engineering 2020* Jan 1 (pp. 279-311). Academic Press.
16. Naik A, Nair H. Formulation and evaluation of thermosensitive biogels for nose to brain delivery of doxepin. *BioMed research international*. 2014 Oct;2014.
17. Yusuf H, Kett V. Current prospects and future challenges for nasal vaccine delivery. *Human vaccines & immune therapeutics*. 2017 Jan 2;13(1):34-45.
18. Costa C, Moreira JN, Amaral MH, Lobo JS, Silva AC. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. *Journal of Controlled Release*. 2019 Feb 10;295:187-200.
19. Hong SS, Oh KT, Choi HG, Lim SJ. Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives. *Pharmaceutics*. 2019 Oct 17;11(10):540.
20. Barnabas W. Drug targeting strategies into the brain for treating neurological diseases. *Journal of neuroscience methods*. 2019 Jan 1; 311:133-46.
21. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. *Physiological reviews*. 2018 Oct 3.
22. Gänger S, Schindowski K. Tailoring formulations for intranasal nose-to-brain delivery: a review on architecture, physico-chemical characteristics and mucociliary clearance of the nasal olfactory mucosa. *Pharmaceutics*. 2018 Aug 3;10(3):116.
23. Upadhyay P, Trivedi J, Pundarikakshudu K, Sheth N. Comparative study between simple and optimized liposomal dispersion of quetiapine fumarate for diffusion through nasal route. *Drug Delivery*. 2016 May 3;23(4):1214-21.
24. Zhao YZ, Lin M, Lin Q, Yang W, Yu XC, Tian FR, Mao KL, Yang JJ, Lu CT, Wong HL. Intranasal delivery of bFGF with nanoliposomes enhances in vivo neuroprotection and neural injury recovery in a rodent stroke model. *Journal of controlled release*. 2016 Feb 28; 224:165-75.
25. Salatin S, Barar J, Barzegar-Jalali M, Adibkia K, Milani MA, Jelvehgari M. Hydrogel nanoparticles and nanocomposites for nasal drug/vaccine delivery. *Archives of pharmacal Research*. 2016 Sep; 39:1181-92.
26. Bernocchi B, Carpentier R, Betbeder D. Nasal nanovaccines. *International Journal of Pharmaceutics*. 2017 Sep 15;530(1-2):128-38.

27. Mato YL. Nasal route for vaccine and drug delivery: Features and current opportunities. *International Journal of Pharmaceutics*. 2019 Dec 15; 572:118813.
28. Tada R, Hidaka A, Iwase N, Takahashi S, Yamakita Y, Iwata T, Muto S, Sato E, Takayama N, Honjo E, Kiyono H. Intranasal immunization with DOTAP cationic liposomes combined with DC-cholesterol induces potent antigen-specific mucosal and systemic immune responses in mice. *PLoS One*. 2015 Oct 6;10(10):e0139785.
29. Arora P, Sharma S, Garg S. Permeability issues in nasal drug delivery. *Drug discovery today*. 2002 Sep 15;7(18):967-75.
30. Machida M, Sano K, Arakawa M, Hayashi M, Awazu S. Effects of surfactants and protease inhibitors on nasal absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. *Biological and Pharmaceutical Bulletin*. 1994 Oct 15; 17(10):1375-8.
31. Watanabe H, Tsuru H. Microcirculation in the nasal mucosa. *Nihon Yakurigaku zasshi. Folia Pharmacologica Japonica*. 1999 Apr 1;113(4):211-8.
32. Comaz AL, Buri P. Nasal mucosa as an absorption barrier. *Eur. J. Phann. Biopharm.* 1994;40(5):261-70.
33. Kumar GP, Kiran S. Strategies and prospects of nasal drug delivery systems. *International Journal of Pharmaceutical Sciences and Research*. 2012 Mar 1;3(3):648.
34. Corbo DC, Liu JC, Chien YW. Characterization of the barrier properties of mucosal membranes. *Journal of pharmaceutical sciences*. 1990 Mar 1;79(3):202-6.
35. sakane T, Akizuki M, Yamashita S, Nadai T, Hashida M, Sezaki H. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. *Chemical and pharmaceutical bulletin*. 1991 Sep 25;39(9):24568
36. Ohwaki K, Ando H, Watanabe S, Miyake Y. Effects of Krenistsky. Amino acid ester prodrugs of acyclovir, Antiviral dose, pH, and osmolarity on nasal absorption of secretin in *Chem Chemother*. 1992; 3:157-64.
37. Behl CR, Pimplaskar HK, Sileno AP, Xia WJ, Gries WJ, Demeireles JC, Romeo VD. Optimization of systemic nasal drug delivery with pharmaceutical excipients. *Advanced Drug Delivery Reviews*. 1998 Jan 5;29(1-2):117-33.
38. Clement P, Roovers MH, Francillon C, Dodion P. Dose-ranging, placebo-controlled study of cetirizine nasal spray in adults with perennial allergic rhinitis. *Allergy*. 1994 Sep;49(8):668-72.

39. Bhowmik D, Kharel R, Jaiswal J, Chiranjib B, Banerjee B, KP SK. Innovative approaches for nasal drug delivery system and its challenges and opportunities. *Annals of Biological Research*. 2010.
40. Aungst BJ. Absorption enhancers: applications and advances. *The AAPS journal*. 2012 Mar;14(1):10-8.
41. Upadhyay S, Parikh A, Joshi P, Upadhyay UM, Chotai NP. Intranasal drug delivery system- A glimpse to become maestro. *Journal of Applied Pharmaceutical Science*. 2011 May 30(Issue):34-44.
42. Singh AK, Singh A, Madhv NS. Nasal cavity, a promising transmucosal platform for drug delivery and research approaches from nasal to brain targeting. *Journal of Drug Delivery and Therapeutics*. 2012 May 14; 2(3).
43. Bhise SB, Yadav AV, Avachat AM, Malayandi R. Bioavailability of intranasal drug delivery system. *Asian Journal of Pharmaceutics (AJP)*. 2008;2(4).
44. Davis SS, Illum L. Absorption enhancers for nasal drug delivery. *Clinical pharmacokinetics*. 2003 Nov;42:1107-28.
45. Hussain AA, Hirai S, Bawarshi R. Nasal absorption of natural contraceptive steroids in rats- progesterone absorption. *Journal of Pharmaceutical Sciences*. 1981 Apr; 70(4):4667.
46. Hussain AA, Hirai S, Bawarshi R. Nasal absorption of propranolol in rats.
47. Djupesland PG, Skretting A. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. *Journal of aerosol medicine and pulmonary drug delivery*. 2012 Oct 1; 25(5):280-9.
48. Laube BL. Devices for aerosol delivery to treat sinusitis. *Journal of aerosol medicine*. 2007 Apr 1;20(s1):S5-18.
49. Hammarlund-Udenaes M. Pharmacokinetic concepts in brain drug delivery. In *Drug delivery to the brain: physiological concepts, methodologies and approaches* 2013 Nov 13 (pp. 127-161). New York, NY: Springer New York.
50. Harmon BT, Aly AE, Padegimas L, Sesenoglu-Laird O, Cooper MJ, Waszczak BL. Intranasal administration of plasmid DNA nanoparticles yields successful transfection and expression of a reporter protein in rat brain. *Gene therapy*. 2014 May; 21(5):514-21.
51. Mistri PA, Patel DJ, Prajapati JJ. Intranasal drug delivery system: a review. *Int J Pharm Innov*. 2012;2(2):43-55.
52. Shimpi S, Chauhan B, Shimpi P. Cyclodextrins: application in different routes of drug administration. *Acta pharmaceutica*. 2005 Jun 1; 55(2):139-56.

53. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. *Aaps Pharmscitech*. 2005 Jun; 6:E329-57.
54. Dhakar RC. Non-invasive systemic drug delivery via nasal route: a review. *African Journal of Pharmaceutical Sciences and Pharmacy*. 2011 Apr 25;2(1).
55. Harshad P, Anand B, Dushyant S. Recent techniques in nasal drug delivery: A review. *Int. J. Drug Dev. Res*. 2010;2(3):565-72.
56. Moghimipour E, Ameri A, Handali S. Absorption-enhancing effects of bile salts. *Molecules*. 2015 Aug 10;20(8):14451-73.
57. Jadhav KR, Gambhire MN, Shaikh IM, Kadam VJ, Pisal SS. Nasal drug delivery system-factors affecting and applications. *Current drug therapy*. 2007 Jan 1; 2(1):27-38.
58. Kushwaha SK, Keshari RK, Rai AK. Advances in nasal trans-mucosal drug delivery. *Journal of Applied Pharmaceutical Science*. 2011 Sep 30(Issue):21-8.
59. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. *International Journal of Pharmaceutics*. 2007 Jun 7;337(1-2):1-24



AJPHR is
Peer-reviewed
monthly
Rapid publication
Submit your next manuscript at
editor@ajphr.com / editor.ajphr@gmail.com